Greg Harrison
Stock Analyst at B of A Securities
(2.15)
# 1,512
Out of 4,412 analysts
25
Total ratings
43.48%
Success rate
-3.34%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Buy | $13 → $15 | $12.53 | +19.71% | 2 | Dec 21, 2023 | |
| BEAM Beam Therapeutics | Downgrades: Neutral | $35 | $21.38 | +63.70% | 2 | Dec 15, 2023 | |
| TVTX Travere Therapeutics | Maintains: Buy | $41 → $27 | $5.26 | +413.31% | 2 | Sep 22, 2023 | |
| KROS Keros Therapeutics | Initiates: Buy | $65 | $57.86 | +12.34% | 1 | Jul 26, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $89 → $91 | $20.76 | +338.34% | 2 | Jun 13, 2023 | |
| STOK Stoke Therapeutics | Upgrades: Neutral | $9 → $12 | $12.41 | -3.30% | 3 | May 1, 2023 | |
| SGMO Sangamo Therapeutics | Downgrades: Underperform | $5 → $1.5 | $0.52 | +189.69% | 1 | Apr 28, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $39 | $11.87 | +228.56% | 1 | Mar 7, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $38 → $35 | $21.98 | +59.24% | 2 | Dec 23, 2022 | |
| EDIT Editas Medicine | Maintains: Neutral | $18 → $15 | $5.32 | +181.95% | 2 | Nov 18, 2022 | |
| OMER Omeros | Downgrades: Underperform | $3 | $3.15 | -4.76% | 1 | Nov 8, 2022 | |
| SNTI Senti Biosciences | Initiates: Buy | $7 | $0.29 | +2,313.79% | 1 | Sep 29, 2022 | |
| RDUS Radius Health | Upgrades: Neutral | $8 | $17.90 | -55.31% | 1 | Jun 8, 2022 | |
| S SentinelOne | Maintains: Buy | $67 → $54 | $21.56 | +150.46% | 1 | Mar 16, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Underperform | $18 → $6 | $1.32 | +354.55% | 2 | Mar 14, 2022 | |
| AGIO Agios Pharmaceuticals | Initiates: Buy | n/a | $31.49 | - | 1 | Dec 3, 2021 |
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $13 → $15
Current: $12.53
Upside: +19.71%
Beam Therapeutics
Dec 15, 2023
Downgrades: Neutral
Price Target: $35
Current: $21.38
Upside: +63.70%
Travere Therapeutics
Sep 22, 2023
Maintains: Buy
Price Target: $41 → $27
Current: $5.26
Upside: +413.31%
Keros Therapeutics
Jul 26, 2023
Initiates: Buy
Price Target: $65
Current: $57.86
Upside: +12.34%
Intellia Therapeutics
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $20.76
Upside: +338.34%
Stoke Therapeutics
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $12.41
Upside: -3.30%
Sangamo Therapeutics
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.52
Upside: +189.69%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $11.87
Upside: +228.56%
Rocket Pharmaceuticals
Dec 23, 2022
Maintains: Buy
Price Target: $38 → $35
Current: $21.98
Upside: +59.24%
Editas Medicine
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $5.32
Upside: +181.95%
Omeros
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $3.15
Upside: -4.76%
Senti Biosciences
Sep 29, 2022
Initiates: Buy
Price Target: $7
Current: $0.29
Upside: +2,313.79%
Radius Health
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $17.90
Upside: -55.31%
SentinelOne
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $21.56
Upside: +150.46%
Nektar Therapeutics
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $1.32
Upside: +354.55%
Agios Pharmaceuticals
Dec 3, 2021
Initiates: Buy
Price Target: n/a
Current: $31.49
Upside: -